Associate Professor Jemma Hopewell
|Tel||+44 (0)1865 743661|
BSc (Hons) MSc PhD (Cantab)
Associate Professor & Senior Scientist in Genetic Epidemiology and Clinical Trials
- BHF Intermediate Basic Science Research Fellow
- MSc in Global Health Science Module Lead: Genetic Epidemiology
Associate Professor Jemma leads a medical statistics and genetic epidemiology team in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a). Jemma leads and collaborates on numerous projects involving CTSU's vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Bowman L. et al, (2017), New England Journal of Medicine
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell JC. et al, (2017), European Heart Journal
Association analyses based on false discovery rate implicate new loci for coronary artery disease.
Nelson CP. et al, (2017), Nat Genet
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation.
Christophersen IE. et al, (2017), Nat Genet, 49, 946 - 952
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190